Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,177.68
(
0.58%
)
US TECH 100
26,570.00
(
0.41%
)
Dow Jones
49,545.35
(
1.40%
)
Brent Oil
108.88
(
-3.11%
)
Bitcoin
76,151.39
(
0.49%
)
News Focus
News Focus

Replies to post #256282 on Biotech Values

Replies to #256282 on Biotech Values
icon url

DewDiligence

10/30/25 3:04 PM

#256291 RE: DewDiligence #256282

More on the same topic:
https://twitter.com/DewDiligence/status/1983971867645112517
icon url

DewDiligence

10/31/25 4:21 PM

#256296 RE: DewDiligence #256282

FTC clears PFE's acquisition of MTSR:

https://finance.yahoo.com/news/pfizer-receives-early-clearance-u-195000773.html

The FTC review was expected to conclude on Nov 7 (one week from today). Hmm…
icon url

DewDiligence

10/31/25 8:04 PM

#256299 RE: DewDiligence #256282

Ha! PFE uses the word, “circumvent” in its lawsuit:

https://www.wsj.com/health/pharma/pfizer-sues-seeking-to-block-novo-nordisks-effort-to-undo-weight-loss-drug-deal-929710b2

In its lawsuit, Pfizer said the structure of Novo Nordisk’s offer for Metsera—a complicated two-step process—is intended to circumvent antitrust review.